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 SPECIAL SELECTION: BROWN FAT 
 Endogenous ways to stimulate brown adipose tissue in humans 
 Evie  Broeders 1,2 ,  Nicole D.  Bouvy 2  &  Wouter D.  van Marken Lichtenbelt 1 
 1 Department of Human Biology, NUTRIM  – School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Centre, 
Maastricht, the Netherlands, and  2 Department of Surgery, Maastricht University Medical Centre, Maastricht, the Netherlands 
 Introduction 
 Changed dietary habits and modern technological developments, 
which contributed to a sedentary lifestyle, have led to a worldwide 
increase in the incidence of overweight and obesity, which has 
now reached epidemic proportions in the Western world (1). Th e 
development of obesity results from a prolonged disequilibrium 
in the energy balance with energy intake exceeding energy expen-
diture, leading to storage of excess calories as fat, both subcutane-
ously and intra-abdominally. In the past decades obesity and its 
accompanying metabolic diseases have emerged to be the second 
most common preventable cause of death in Western society. Th e 
present therapeutic options for correcting the caloric imbalance 
causing obesity include both therapies focusing on decreasing 
energy intake and exercise programs to enhance energy expendi-
ture. However, successful long-term weight loss defi ned as losing 
10% of the initial body weight and maintaining the loss for at least 
one year is only achieved in around 20% aft er these programs. 
Due to the ineff ectiveness of the existing treatments, there is a 
need to explore other strategies. Lately, prescription weight loss 
medication and bariatric surgery have received strong scientifi c 
attention in treatment of (morbid) obesity. Furthermore, cold-
stimulated adaptive thermogenesis in brown adipose tissue (BAT) 
is suggested as a possible therapeutic target for the prevention and 
treatment of obesity and associated metabolic diseases (2). 
 In recent years, more knowledge about the function and 
induction of BAT has been obtained. Th e sympathetic nervous 
system (SNS) is currently seen as the main eff ector for brown fat 
function. Also, interplay between the thyroid axis and SNS has 
been identifi ed to play an important role in BAT thermogenesis. 
Studies both in animals and in man show diff erent ways in which 
BAT thermogenesis can be regulated and stimulated. Here we 
will discuss the relevance of several pathways for activating BAT, 
and their implications for the treatment of obesity. In this review 
of both human and experimental studies we will discuss several 
pathways for endogenous BAT activation. We will focus on the 
discussion of the most promising endocrine and paracrine path-
ways in humans to stimulate BAT, via factors or pathways that 
naturally occur in the human body. 
 BAT: function and detection 
 BAT function and regulation of thermogenesis in BAT 
 Th e main function of white adipose tissue (WAT) is energy stor-
age; the cells have large fat droplets and minimal numbers of 
mitochondria. Brown adipose tissue (BAT), on the other hand, 
is specifi cally designed to generate heat, with cells containing 
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 Key message 
 Th e interplay between the diff erent pathways described  •
in this review points towards the need to target not 
only specifi c factors but to take into account these 
interactions. 
 Obesity is the result of disequilibrium between energy intake 
and energy expenditure (EE). Successful long-term weight loss 
is diffi  cult to achieve with current strategies for the correction 
of this caloric imbalance. Non-shivering thermogenesis (NST) in 
brown adipose tissue (BAT) is a possible therapeutic target for the 
prevention and treatment of obesity and associated metabolic 
diseases. In recent years, more knowledge about the function 
and stimulation of bat has been obtained. The sympathetic ner-
vous system (SNS) is currently seen as the main eff ector for brown 
fat function. Also, interplay between the thyroid axis and SNS 
plays an important role in BAT thermogenesis. Almost daily new 
pathways for the induction of BAT thermogenesis and  ‘ brown-
ing ’ of white adipose tissue (WAT) are identifi ed. Especially the 
activation of BAT via endogenous pathways has received strong 
scientifi c attention. Here we will discuss the relevance of several 
pathways in activating BAT and their implications for the treat-
ment of obesity. In this review we will focus on the discussion 
of the most promising endocrine and paracrine pathways to 
stimulate BAT, by factors and pathways that naturally occur in the 
human body. 
 Key words:  Anti-obesity therapy ,  beige adipocytes ,  brown adipose 
tissue ,  endocrine factors ,  non-shivering thermogenesis ,  paracrine 
factors ,  UCP1 
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multiple fat vacuoles and numerous mitochondria, giving the tis-
sue its brown color. Th e functional diff erence between the two 
types of fat found in the human body is highlighted by the high 
sympathetic innervation and vascularization of BAT. 
 BAT is widely known to have the ability to burn off  excess en-
ergy in a process called mitochondrial uncoupling. Th is unique 
response is facilitated by a mitochondrial membrane protein 
called UCP1 (uncoupling protein one, thermogenin), which is 
used as a marker for brown adipose tissue. UCP1 has the abil-
ity to uncouple the normal respiration chain, utilizing the proton 
gradient across the mitochondrial membrane to generate heat in 
response to cold (non-shivering thermogenesis (NST)) instead of 
using it for adenosine triphosphate (ATP) production (3), pro-
foundly increasing energy expenditure. Stimulation of this cold-
induced, UCP1-dependent increase in energy expenditure might 
be benefi cial in the treatment of obesity and associated metabolic 
diseases. 
 Recent  in vitro studies have shown that the quantity and 
functional activity of brown adipocytes can be regulated. Brown 
adipocytes and skeletal muscle cells arise from  myf5 progenitors. 
Several transcriptional coactivators, such as PRDM16 (4), PGC1 α 
(peroxisome proliferator-activated receptor gamma coactivator 
1-alpha) (5) and growth factors like BMP7 (bone morphogenetic 
protein 7) have been identifi ed that can infl uence the diff erentia-
tion process of pre-adipocytes into white or brown phenotypes 
(4). Stimulation of white fat with these factors has been identifi ed 
to stimulate the development of active thermogenic brown-like 
adipocytes within white fat depots. Th ese cells are not typical 
brown adipocytes, but they form a particular type of adipocytes, 
named  ‘ beige ’,  ‘ brite ’, or  ‘ brown-in-white ’ adipocytes. 
 Besides the  ‘ browning ’ of white adipose tissue, BAT can also be 
recruited. Recent work has shown that a 10-day acclimation pe-
riod leads to increased energy expenditure and increased glucose 
uptake in typical BAT locations, indicating BAT or brite recruit-
ment in adult humans (6). Th is too might be of great importance 
in targeting obesity in the future, as adjustments of ambient 
temperature in everyday life might have benefi cial eff ects on BAT 
presence and, if environment temperatures are low enough, on 
thermogenesis in BAT. 
 Visualization of BAT using [ 18 F]FDG PET-CT and 
cold exposure 
 Functional BAT in adult humans was discovered by 2- 18 F-
fl uoro-D-glucose positron-emission-tomography-and-computer-
tomography ([ 18 F]FDG PET-CT) fusion imaging, used in nuclear 
medicine to depict glucose uptake for tumor diagnosis. 
 In the past decades [ 18 F]FDG uptake in the neck and 
supraclavicular regions, which could not be explained by normal 
structures or pathology of oncologic origin, was regularly seen 
during this routine oncologic imaging. Th ese fi ndings soon led to 
the discovery that the uptake is mapping areas of adipose tissue 
in the supraclavicular and neck area and is related to mild cold 
conditions in the room during administration of the tracer. In 
2003 a total of 863 PET-CT scans were evaluated. Non-pathologic 
[ 18 F]FDG activity was observed in adipose tissue in the neck and 
shoulder region, axillae, mediastinum, and perirenal regions (7). 
Tissue biopsies from PET-active supraclavicular tissue confi rmed 
BAT presence, responsible for the glucose uptake (8,9). Since 
this discovery the interest in the possibilities of this thermogenic 
organ increased exponentially. Because of its high heat produc-
tion capacity in rodents, the stimulation of BAT in man is seen as 
an anti-obesity target (3). 
 Although [ 18 F]FDG PET-CT is currently the most used 
technique for depicting metabolically active BAT in humans, there 
are signifi cant limitations to this method. Mainly the radiation 
exposure associated with PET-CT imaging precludes repeated 
imaging of BAT in healthy young subjects (10). Moreover, [ 18 F]
FDG PET-CT scanning visualizes glucose uptake, but does not 
provide information on the uptake of fatty acids, the most impor-
tant alternative energy source, and oxidative metabolism. Fatty 
acid uptake in BAT can be visualized by using a fatty acid tracer, 
like  18 F-fl uoro-thiaheptadecanoic acid ( 18 FTHA), instead of a 
glucose tracer. BAT visualization by means of  123 I-MIBG SPECT-
CT is currently being evaluated by several groups. A recent study 
showed that  123 I-MIBG SPECT-CT and [ 18 F]FDG PET-CT identify 
the same anatomic regions as active BAT. Also, there was a strong 
correlation between the magnitudes of BAT activity measured by 
both techniques (11). Possibly, in the future  123 I-MIBG SPECT-CT 
could be used as a visualization method for BAT. Another attrac-
tive method for the study of BAT is MRI. Th e main advantage of 
MRI over PET-CT scanning is that MRI does not deliver mutagenic 
radiation (12). Also, with MRI a more reliable distinction between 
BAT and WAT can be made based on water content of the tissue, 
which is 50% and 10%, respectively (13). 
 Cold exposure is an important activator of BAT (3). Besides 
the direct eff ect of cold exposure on BAT activity, animal studies 
have also shown that there is a positive eff ect of long-term cold 
exposure on NST and BAT recruitment. Recently two studies in 
humans showed results in line with these earlier fi ndings in ro-
dents and primates. In one study healthy subjects were exposed to 
mild cold environment (15 – 16 ° C) for up to 6 hours a day, for 10 
consecutive days, aft er which they showed a signifi cant increase in 
brown adipose tissue activity (upper body BAT activity 2.4    0.7 
SUV (standard uptake value) mean before cold acclimation versus 
2.8    0.5 SUV mean aft er cold acclimation,  P    0.01) in parallel 
with increased energy expenditure (10.8%    7.5% before cold ac-
climation versus 17.8%    11.1% aft er cold acclimation,  P   0.05). 
Furthermore, cold tolerance seemed to increase in these subjects 
during the course of the cold acclimation period, as subjects 
tended to report more comfort and less shivering towards the end 
of the cold acclimation period (6). In the second study healthy 
adults were subjected to a daily 2-hour cold exposure at 17 ° C for 
6 weeks. Th is cold acclimation protocol resulted in an increase 
in BAT activity from 2.46    0.40 to 3.89    0.64 SUV ( P    0.01) 
accompanied with a signifi cant increase in energy expenditure 
(EE) (14). 
 A recent paper showed that a minimal decrease in ambient 
temperature already leads to induction of BAT activity. Subjects 
were exposed to a temperature of 19 ° C, aft er which an [ 18 F]FDG 
PET-CT scan was performed. BAT activity increased signifi cantly 
and was positively correlated with individual NST responses (15). 
 Endogenous ways for activation of BAT in humans 
 Sympathetic stimulation (SNS/catecholamines) 
 Despite the many hypotheses regarding the most eff ective mecha-
nisms for BAT activation, there is a general consensus that BAT 
is under direct control of the sympathetic nervous system (SNS). 
Following cold exposure, BAT is stimulated by the SNS to generate 
heat, most likely through temperature-sensitive neurons located 
in the skin (16). Th ermogenesis in BAT is regulated by responses 
from these neurons, which are mediated and controlled in the 
preoptic area of the hypothalamus. Within this central network 
controlling BAT activation, medullary sympathetic premotor 
neurons seem to play a vital role. GABA (gamma-aminobutyric 
acid)-ergic neurons in this hypothalamic area are activated, which 
causes disinhibition of neurons in the dorsomedial hypothalamus, 
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which project to the medulla oblongata, where the projections are 
conveyed into sympathetic stimuli. Th e consequential release of 
norepinephrine at the nerve endings causes BAT activation, due 
to binding to  β -adrenergic receptors on the cell surface of BAT 
cells, which induces expression of uncoupling protein-1 (16). 
 Th e level of heat production in BAT depends mainly on the 
degree of activation of BAT sympathetic nerves, the extent of 
subsequent norepinephrine release, and the intensity of binding 
of released norepinephrine to the adrenergic receptors. Adren-
ergic stimulation of BAT increases intracellular cAMP (cyclic 
adenosine monophosphate) release and activates protein kinase A 
(PKA), leading to the expression of thermogenic genes and tran-
scriptional regulators as well as activation of fueling enzymes for 
mitochondrial oxidation of lipids (17). In addition, the subtype 
of the  β -receptor that is targeted is essential for the extent of BAT 
thermogenesis accomplished, with the  β 3-receptor subtype being 
the most eff ective activator for BAT thermogenesis (3). 
 Animal viral tracing studies have shown that the neurons 
within the spinal cord, forebrain, and brainstem play a key role 
in controlling BAT thermogenesis (18). Especially the medulla is 
of importance, as this area contains one or more of the following 
markers that are known to infl uence BAT sympathetic neurons: 
the vesicular glutamate receptor 3 (VGLUT3), serotonin (5-HT) 
or tryptophan hydroxylase, which is a synthetic enzyme for sero-
tonin, and glutamic acid decarboxylase-67 (GAD-67), a specifi c 
marker for GABA-ergic neurons (19). 
 Serotonergic agents are known for their potential to aff ect me-
tabolism. However, little knowledge about the neural pathways 
in which serotonin (5-hydroxytryptamine (5-HT)) aff ects energy 
expenditure has been obtained. Recently, involvement of the glu-
tamate and serotonin system in BAT sympathetic nerve activity 
was demonstrated in a rat model. Aft er activation of 5-HT 1A /5-
HT 7 receptors, by direct injection of a receptor agonist into the 
spinal cord, sympathetic nerve activity outfl ow to BAT increased. 
Furthermore, 5-HT receptor stimulation potentiates BAT re-
sponse to glutamate (20). Th is is demonstrated in recent studies, 
in which combined activation of the serotonin and glutamate re-
ceptors lead to a synergistic eff ect of the two, markedly increasing 
sympathetic activation of BAT (21). 
 Th e importance of the SNS in BAT activation and function 
in humans is emphasized in recent studies. Pheochromocytoma 
patients, characterized by elevated plasma levels of catecholamine 
due to secretion of norepinephrine and epinephrine by a neu-
roendocrine adrenal gland tumor, showed high BAT activity on 
[ 18 F]FDG PET-CT imaging, which disappeared aft er resection of 
the tumor (22). In contrast, blocking of adrenergic receptors with 
a receptor antagonist (propranolol, non-selective  β -antagonist) 
completely diminished FDG uptake in BAT areas, suggesting the 
involvement of these adrenergic receptors in BAT activation in 
humans (23). Very few studies have investigated the eff ects of SNS 
stimulation on BAT activity. A recent study from 2012 showed 
no stimulatory eff ect of the sympathomimetic ephedrine, which 
was given in a single intramuscular dose of 1 mg/kg bodyweight, 
on BAT activity. SUV maximum values remained at baseline level 
aft er administration of ephedrine (24). Another study in humans, 
in which the non-selective  β -adrenergic agonist isoprenaline was 
used to mimic  β -adrenergic SNS activity, showed similar results. 
Aft er intravenous administration of incremental doses of iso-
prenaline (6, 12, and 24 ng per kg fat-free mass) in 9 out of the 
10 subjects no detectable [ 18 F]FDG-uptake in BAT regions was 
observed, whereas cold stimulation in the same subjects did, as 
expected, lead to an increased BAT activity compared to baseline. 
However, this unexpected fi nding is possibly due to insuffi  ciently 
high systemic concentrations of isoprenaline, much lower than at 
the nerve ending, leading to insuffi  cient triggering of  β -receptors 
on brown adipocytes (25). Furthermore, adrenergic agents such 
as ephedrine and isoprenaline are non-selective  β -agonists. Stim-
ulation of the SNS by administration of these agents will lead to 
 β 1-mediated stimulation of the cardiovascular system (increased 
blood pressure and heart rate), whereas for BAT stimulation the 
 β 3-receptor seems to be the main eff ector for thermogenesis (22), 
as suggested from studies in which BAT activity aft er  β 3 stimula-
tion was compared with BAT activity aft er norepinephrine admin-
istration (3). Furthermore, blocking of the  β 1- and  β 2-adrenergic 
receptors through administration of propanolol decreases BAT 
activity under thermoneutral circumstances, demonstrating the 
involvement of  β -adrenergic receptors in BAT thermogenesis in 
humans (23). Unfortunately, administration of most  β -adrenergic 
agents is accompanied by a variety of potentially harmful side 
eff ects, such as hypertension, tachycardia, anxiety, and head-
aches. Possibly, increasing BAT activity through induction of this 
complex system via safe medicinal products, free of unbenefi -
cial side eff ects, could be a future target for the prevention and 
treatment of obesity. Especially, the development and eff ects of 
 β 3-receptor-specifi c agonists still needs further attention. 
 Thyroid hormones 
 In addition to direct sympathetic stimulation, endocrine stimula-
tion also aff ects BAT thermogenesis in animals. Th e thyroid gland 
secretes the two forms of thyroid hormone, triiodothyronine and 
thyroxine (T3 and T4, respectively). T3 and T4, which are known 
to play a key role in thermogenesis in humans, are secreted into 
the blood-stream in response to high circulating plasma levels of 
thyroid-stimulating hormone (TSH) or in response to cold (26). 
Ninety-fi ve percent of the hormones secreted by the thyroid gland 
will be the inactive pro-hormone thyroxine (T4), that needs to 
be activated in target cells by deiodinases, forming the hormone 
triiodothyronine (T3). T3 has signifi cant positive eff ect on en-
ergy expenditure in humans, as is illustrated by clinical states of 
hypo- or hyperthyroidism where energy expenditure respectively 
decreases or increases (27). In rodents, thyroid hormone has been 
known to be an activator of BAT. Aft er conversion of T4 to T3 
by the BAT-specifi c type 2 deiodinase (D2), thyroid hormone 
enhances thermogenesis in BAT (28) Figure 1. 
 Th is T3-mediated increase in energy expenditure occurs 
through binding of T3 on thyroid nuclear receptor TR α 1 (thyroid 
receptor 1 alpha), found on brown adipocytes. Th yroid-stimulat-
ing hormone (TSH), secreted by thyrotrophic cells in the anterior 
pituitary gland, stimulates the thyroid gland to release T4. Inter-
estingly, TSH itself also seems to be involved in thermogenesis. 
TSH receptor expression has been identifi ed in a variety of cell 
types, including BAT in rats (29). Th is suggests interplay between 
TSH and thyroid hormones responsible for the thyroid eff ect on 
BAT function. 
 Recent studies have shown that treatment of human stem cells 
with T3 stimulates the development of UCP1-positive cells within 
white adipose tissue (30). Since UCP1 is the protein that facilitates 
mitochondrial uncoupling in BAT, this suggests thyroid hormone 
signifi cantly aff ects  ‘ browning ’ of WAT in humans. 
 Nevertheless, without thyroid stimulation BAT can still 
become active. When D2-defi cient mice are exposed to cold, 
thermogenesis is still accomplished by stimulation via the sympa-
thetic nervous system and the limited availability of active plasma 
thyroid hormone. However, when these animals are not exposed 
to cold, they develop glucose intolerance, non-alcoholic fatty liver 
disease (NAFLD), and diet-induced obesity (31). Th is suggests 
that thyroid-induced, D2-dependent BAT activity is important to 
prevent development of these diseases. 
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 Figure 1. Molecular endogenous pathways regulating brown adipose tissue function. AR    adrenergic receptor; BAs    bile acids; BMP7    bone morphogenetic 
factor type 7; cAMP    cyclic adenosine monophosphate; D2    type 2 deiodinase; FGF21    fi broblast growth factor 21; FGF-KLBR    fi broblast growth 
factor- Klotho- β receptor; NE    norepinephrine; NPRA    natriuretic peptide receptor; NPs    natriuretic peptides; p38 MAPK    cytokinin specifi c binding 
protein mitogen-activated protein kinase; PKA    protein kinase A; PKG    cyclic guanosine monophosphate-dependent protein kinase; RA    retinoic acid; 
T3    triiodothyronine; T4    thyroxine; TGR5    transmembrane G protein-coupled receptor 5; TR    thyroid hormone receptor; UCP1    uncoupling protein 
1; VEGF    vascular endothelial growth factor; VEGFR    vascular endothelial growth factor receptor. 
 Besides the direct infl uence of thyroid hormone on the brown 
adipocyte, thyroid hormone could also induce BAT activity 
centrally by stimulating the hypothalamic pathway. In rats in a 
hyperthyroid state the excess thyroid hormone seems to alter 
hypothalamic AMPK (5 ′ adenosine monophosphate-activated 
protein kinase)-dependent activation of  de novo lipogenesis, 
resulting in increased dissipation of energy in BAT and associ-
ated weight loss (32). Th us, thyroid hormone seems to aff ect BAT 
activity both at cellular level during cold exposure and at the brain 
level regardless of temperature. A case report of a patient with 
extreme insulin resistance and thyroid gland cancer seems to sup-
port this theory. Th e therapeutic treatment of this condition with 
high doses of thyroid hormone was accompanied with active BAT 
on PET-CT, in the absence of a cold stimulus (33). Interestingly, 
thyroid hormone treatment also resolved the hyperglycemia of 
this patient, suggesting a role for BAT in glucose metabolism. 
In a larger study cohort, increased insulin resistance was associ-
ated with a D2 gene mutation. Moreover, if this D2 mutation was 
accompanied by a mutation in the  β 3-adrenergic receptor, BMI 
(body mass index) was signifi cantly higher (34). 
 In summary, the synergism between the sympathetic nervous 
system and thyroid axis seems to be of great importance in the 
control of BAT-mediated thermogenesis. During hypothyroidism, 
BAT activity could be impaired, which could lead to overweight 
and associated co-morbidities (e.g. insulin resistance). Th erefore, 
BAT-targeted thyroid thermogenesis could be a target for obesity 
treatment (35). 
 FNDC5/irisin 
 Exercise is known for its benefi cial eff ects on a variety of organ 
systems and is essential in weight loss strategies as a tool to burn 
off  excess calories. Exercise leads to massive activation of the SNS, 
but it remains unclear whether this is accompanied by increased 
BAT activity. Several animal studies have addressed this issue, 
with ambiguous results. So far, most studies (36) found no ex-
citatory eff ect of exercise on BAT activity, except for those cases 
where 6-week swimming training protocols were followed (37). 
 Recent insights in rodent studies have led to the conclusion 
that exercise does have stimulating eff ects on brown adipose 
tissue development. In 2012 exercise training was reported to 
result in browning of subcutaneous fat tissue. In this context, 
muscle has been identifi ed as an endocrine organ releasing various 
cytokines (myokines) for the regulation of metabolic and physio-
logical pathways (38). Irisin, fi rst discovered in a mouse model, is 
a by-product of muscle proteolysis of FNDC5 (fi bronectin type 3 
containing 5), a membrane protein. Aft er the release of irisin into 
the blood-stream, it is reported to exert hormone-like functions 
on WAT. Mice with overexpression of PGC1 α , a transcriptional 
coactivator for several biological programs related to metabo-
lism, were found to have increased browning in WAT from the 
inguinal area. Exercise is also known to lead to increased PGC1 α 
expression, and the eff ects of endurance training on browning of 
WAT were found to be similar. PGC1 α -mediated expression of 
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the membrane protein FNDC5 gene, and irisin, in muscle tissue 
(39) was shown to contribute to increased mRNA expression of 
PRDM16 and PGC1 α ,  ‘ browning ’ and thermogenic capacity of 
subcutaneous white adipose tissue by increased UCP1 expression 
(5). Th is was observed in both adipocyte culture and in mouse 
models. Improved glucose tolerance was achieved in mice on a 
high-fat diet by adenovirus-mediated overexpression of liver 
FNDC5 mRNA and consequential 3 – 4-fold increase in plasma 
irisin levels (39). 
 Earlier studies had failed to provide equally successful 
results. Acute eff ects of running lead to a transient increase in SNS 
activity accompanied with heat production. However, long-term 
training studies found neither changes in total RNA content and 
UCP1 gene expression (40) nor reduction in BAT UCP1 expres-
sion (41). Furthermore, whole-body NST and blood fl ow to BAT 
did not diff er between exercised and sedentary rats (36). Another 
study in human subjects showed no increase in FNDC5 mRNA in 
muscle biopsy tissue aft er exercise (42). A recent study provides 
evidence against a benefi cial eff ect of irisin in humans. Genomic 
DNA, mRNA, and expressed sequence tags showed a mutation in 
the FNDC5 start codon, resulting in only 1% full-length protein. 
Furthermore, treatment of isolated human preadipocytes with 
both FNDC5 and irisin showed no eff ect on diff erentiation to 
brite adipocytes, suggesting that the positive association of irisin 
on the  ‘ browning ’ of WAT that is observed in mice is unlikely to 
exist in humans (43). 
 In order to gain more insight in the physiological mechanisms 
in which irisin aff ects the human body, and especially human 
metabolism, prospective studies in human subjects are needed. 
 Cardiac natriuretic peptides (ANP/BNP) 
 A study from 2012 suggests that natriuretic peptides (NPs) are 
involved in the browning of white adipocytes in both mouse 
models and human subjects (44). NPs were fi rst discovered in 
1981, when they were known to be involved in hemodynamic 
homeostasis. Atrial natriuretic peptide (ANP) is a powerful 
vasodilatator, which is secreted by cells of the atria of the heart 
in response to high blood pressure and acts to reduce the water, 
sodium, and adipose loads on the circulatory system, thereby re-
ducing blood pressure. Brain natriuretic peptide (BNP) is secreted 
by the ventricles of the heart in response to excessive stretching 
and decreases systemic vascular resistance and central venous 
pressure but increases natriuretic potential. 
 A recent review suggests that, besides regulation of blood pres-
sure and blood volume, NPs might also be involved in energy 
homeostasis (45). In 2000 NPs were identifi ed to play a role in 
lipolysis in human adipose tissue and increase plasma levels of 
non-esterifi ed fatty acids. Treatment of adipocyte cultures from 
wild-type mice with ANPs showed increased lipolysis in these 
adipocytes. In human subjects undergoing ANP-infusion, similar 
rises in lipolysis rate were observed (46). Interestingly, plasma 
levels of NPs seem to be suppressed in obese subjects (47). 
 Also, circulating levels of NPs are negatively related to type 2 
diabetes incidence, and some studies even identifi ed low levels of 
NPs as a predictor for the development of this disease (48). 
 Th e study of Bordicchia et  al. (44) demonstrated a thermogen-
ic eff ect of NPs in mice and in human adipocytes diff erentiated 
from human multipotent adipose-derived stem cells. According 
to the fi ndings in this study, the mechanism of increasing typical 
brown fat thermogenesis, as eff ective as catecholamine-induced 
BAT thermogenesis, works through activating guanylyl cyclase 
containing natriuretic peptide receptor A (NPRA), which in turn 
activates the second messenger cyclic guanosine monophosphate 
(cGMP). Th is second messenger activates cGMP-dependent 
protein kinase (PKG) (49), which is capable of phosphorylating 
key targets in the fat cell, like hormone-sensitive lipase (HSL) 
and perilipins (50). ANP-induced activation of AMPK enhanced 
mitochondrial capacity and treatment of diff erentiated multi-
potent adipose-derived stem cells with ANP lead to increased 
expression of UCP1, PGC1 α , cytochrome c, and PRDM16 (44). 
Th e capacity of ANPs to modify the expression of these key 
regulators of the brown adipocyte phenotype has been shown to 
be comparable to that of the non-selective  β -adrenergic recep-
tor agonist isoproterenol and the  β 3-adrenergic receptor agonist 
L755,507, the latter two being known for their high capacity to 
enhance the transcription of genes promoting the browning of 
adipocytes and genes involved in respiratory uncoupling in brown 
adipose tissue (44). BNP infusion in mice for a period of 7 days 
was associated with increased energy expenditure and browning 
of white adipose tissue (44). Also, in human subjects an increase 
in postprandial energy expenditure was observed aft er ANP infu-
sion at a rate of 25 ng/kg/min (51). 
 In conclusion, NPs are related to thermoregulation and nega-
tively correlated to obesity and obesity-related metabolic diseases, 
like type 2 diabetes, in humans. In the future, NPs could be useful 
activators of BAT in the quest to prevent and treat the obesity 
epidemic. 
 Insulin 
 Insulin is known to be responsible for GLUT4 (glucose transport-
er type 4)-mediated glucose uptake in brown adipose tissue. For 
a long time lipid combustion was seen as the major fuel source 
for brown adipose tissue, but studies have shown that aft er UCP1 
activation heat production in BAT is a resultant of both glucose 
and fat combustion (52). So besides fatty acids, glucose is taken 
up by BAT and can act as a fuel for mitochondrial uncoupling 
(3), leading to heat energy dissipation, weight loss, and lowered 
plasma glucose levels. Although fatty acid oxidation accounts 
for the major part of cold-induced thermogenesis in brown adi-
pocytes, glucose metabolism is also high during cold exposure. 
Where free fatty acids are a necessity for activation of UCP1, once 
activated both lipids and carbohydrates are used as sources of fuel 
by this tissue. In fact, in isolated brown adipocytes glucose uptake 
and thermogenesis are closely linked (52), as demonstrated by the 
absence of norepinephrine-induced increase in glucose uptake in 
UCP1-ablated mice, which is evident in the presence of UCP1 
(53). Besides acting as a fuel for BAT thermogenesis, glucose 
could also have anaplerotic eff ects and enhance the functioning 
of the Krebs cycle in the form of pyruvate, providing ATP for cell 
functioning (54). 
 Studies in genetically obese diabetic rodents showed that these 
animals have lower body temperature than lean non-diabetic con-
trols, die of hypothermia upon cold exposure, and have only 50% 
of the BAT thermogenic capacities that normal animals have due 
to impaired BAT activity. Despite the similarities of these fi nd-
ings to results in studies with genetically obese but non-diabetic 
mice, some studies indicate that not the obesity per se but the 
accompanying insulin resistance is, at least partly, responsible 
for the reduction in non-shivering thermogenesis in BAT (55). 
In many animal models of obesity insulin resistance and defec-
tive BAT thermogenesis are clearly associated (56). However, a 
direct causation between reduced NST and insulin resistance was 
not proved. Recent human studies under thermoneutral condi-
tions have confi rmed the fi ndings in animal studies and indicate 
reduced glucose uptake and BAT activity in obese and diabetic 
subjects (57). BAT activity was found to be negatively associated 
with plasma glucose values (58). Transplantation of BAT from 
donor mice to age- and sex-matched recipient mice resulted in 
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signifi cantly (67). Long-term studies in diet-induced obese mice 
showed reversal of hepatic steatosis, decreased hepatic glucose 
production, and increased insulin-mediated uptake of glucose in 
the heart, adipose tissue, and skeletal muscle aft er treatment with 
recombinant FGF21 for 3 – 6 weeks (67). 
 Activation of fi broblast growth factor 21 (FGF21) is known 
to play an important role in free fatty acid (FFA) oxidation, li-
polysis, and ketogenesis during fasting. Besides FGF21 expression 
in liver, WAT, skeletal muscle, and the pancreas, recently FGF21 
expression has been identifi ed in BAT (68). Treatment of neonatal 
BAT and isolated adipocytes with recombinant FGF21 promotes 
thermogenic activity. Systemic administration of FGF21 in mice 
leads to expression of thermogenic genes in BAT, associated with 
cold-induced thermogenesis, like UCP1 and type 2 deiodinase 
(69). Expression of these genes results in enhanced mitochondrial 
uncoupling in BAT mitochondria and enhanced conversion of 
the inactive T4 thyroid hormone into the active T3, also stimu-
lating BAT activity. Aft er cold exposure or selective  β -adrenergic 
stimulation FGF21 is overexpressed in BAT, leading to the tran-
scription of UCP1 and browning of WAT, by enhanced adipose 
tissue PGC1 α mRNA levels, which is a thermogenic coactivator 
leading to increased mitochondrial gene expression of UCP1 and 
oxidative function in BAT (70). 
 In a recent human study, augmented FGF21 levels correlated 
positively with NST (71). Th ese results strongly suggest that 
FGF21 expression induces NST and could have benefi cial eff ects 
on BAT activity. 
 Because FGF21 acts on and reverses aspects of the obesity 
metabolic profi le, it has great potential as a therapeutic target 
for treatment of the metabolic syndrome in the future. However, 
FGF21 may cause bone loss due to enhanced diff erentiation of 
bone marrow mesenchymal stem cells to adipocytes instead of 
osteoblasts (72). Th erefore more research is needed before FGF21 
could be implemented as an anti-obesity drug. Also, the eff ect of 
FGF21 enhancement by cold exposure on BAT activity in humans 
should be investigated. 
 Bile acids 
 Recently, bile acids (BAs) have been implicated to play a role in 
energy metabolism and BAT functioning. BAs have long been 
known to be essential factors in lipid metabolism and cholesterol 
catabolism (73), the latter being the major route for elimination 
of surplus cholesterol from the body (74). Four major types of 
BAs are known: the primary BAs cholic acid (CA) and chenode-
oxycholic acid (CDCA) and the secondary BAs deoxycholic acid 
(DCA) and lithocholic acid (LCA), which are converted from 
primary BAs by bacterial enzymes in the intestines (75). 
 BA metabolism has been implicated in the regulation of 
energy metabolism. BAs were shown to be natural ligands to the 
nuclear farnesoid X receptor (FXR) (76). Th is receptor controls 
the synthesis and enterohepatic circulation of BAs by adjusting 
the expression of a program of essential gene components that 
are involved in BA synthesis, transportation, conjugation, and de-
toxifi cation (77). Recently, a study reported that FXR defi ciency 
improves glucose homeostasis in a mouse model for the metabolic 
syndrome (78). Also, it was established that a synthetic FXR ago-
nist (GW4064) deteriorates metabolic control in a diet-induced 
obesity mouse model (79). However, other studies show that BAs 
bind to the FXR receptor, stimulating FGF19 transcription, and 
several FXR/bile acid response elements have been identifi ed in 
the FGF19 gene (80). FGF19 is a member of the fi broblast growth 
factor family, as described above (section 3.6), and has an impor-
tant function as a hormone produced in the ileum in response 
to bile acid absorption. It is also known to regulate new bile 
benefi cial eff ects on glucose tolerance, insulin sensitivity, body 
weight, and fat mass aft er 8 – 12 weeks. Furthermore, insulin-
simulated glucose uptake in BAT, WAT, and heart muscle was 
improved (59). Rodent studies performed aft er fasting or aft er 
chronic administration of a high-fat diet, in which insulin levels 
are low or subjects have become insulin-resistant, respectively, 
also show reduced uptake of glucose in brown adipose tissue 
(3). Although recently the prevalence of [ 18 F]FDG-detected BAT 
was proven to be negatively associated with diabetes status (57), 
no acute positive eff ect of insulin on BAT respiration has been 
identifi ed  in vivo . Insulin might play a role in BAT thermogenic 
capacity by modulating the response of BAT to norepinephrine 
and controlling of mitochondrial uncoupling protein expression. 
Injection of insulin directly into the hypothalamus in mice in-
creased BAT activity on PET-CT imaging, resulting in enhanced 
thermogenesis (60). Combining insulin injection with cold ex-
posure was found to synergistically enhance glucose uptake in 
BAT (61). Furthermore, in UCP1-ablated mice glucose uptake in 
BAT was absent (53). A recent human study, with infusion of in-
sulin into the blood-stream, has shown that BAT glucose uptake 
increased 5-fold compared to glucose-uptake in brown adipose 
tissue at baseline (62). However, no direct evidence of impaired 
BAT activity and BAT thermogenesis in diabetic human subjects 
is available. In order to obtain data on the full eff ect of insulin 
resistance on BAT thermogenic capacity BAT activity upon mild 
cold exposure in diabetic humans should be investigated. Also, it 
would be interesting to study the eff ect of insulin on BAT glucose 
uptake and eff ects on energy expenditure. 
 In conclusion, insulin can stimulate glucose uptake in BAT (at 
least in a thermoneutral environment). Th e development of in-
terventions to promote insulin-stimulated glucose uptake in BAT 
could be a therapeutic target for obesity and diabetes. 
 FGF21 
 Fibroblast growth factors (FGFs) are heparin-binding proteins 
known as paracrine factors involved in in the control of cell growth 
and diff erentiation. Th e members of the FGF21 (fi broblast growth 
factor 21) subfamily (including FGF21, FGF19, and FGF23) diff er 
from the other FGF proteins in that they have virtually no mito-
genic eff ects (63). Also, they exert hormone-like functions, due to 
lack of the heparin-binding domain, which allows them to move 
freely from the tissue in which they are expressed to the circula-
tion to act as systemic hormones. 
 Besides the involvement of FGFs in cell development and sur-
vival recent studies suggest a role for members of the FGF21 sub-
family, and especially FGF21, in energy homeostasis. FGF21 (the 
factor, not the subfamily) is expressed for the main part in the liver, 
pancreas, skeletal muscle, but also WAT and BAT. FGF21 binds to 
the FGF receptor (FGFR) in target cells and activates them only in 
the presence of the  β -Klotho transmembrane protein, which acts 
as a cofactor for effi  cient signaling (64). All positive metabolic 
eff ects of FGF21 diminished in whole-body and adipose tissue-
selective  β -Klotho-knock-out mice, which demonstrates the re-
quirement of tissue-specifi c expression of FGFR and  β -Klotho as 
a cofactor in determining the extent of the metabolic activity by 
FGF21 – FGF21 receptor interaction (65). 
 In 2005 the therapeutic potential of FGF21 in counteracting 
metabolic diseases associated with obesity was fi rst described. 
Treatment of mouse adipocytes and also primary cultures of hu-
man adipocytes with FGF21 led to increased glucose uptake in 
these cells (66). Short-term administration of synthetic FGF21 to 
both obese, diabetic mice and rhesus monkeys has been shown 
to have profound eff ects. Plasma glucose levels were lowered, 
energy expenditure increased, and insulin sensitivity improved 
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and metabolism. Recent work showed that retinoids can act as 
inducers of UCP1 gene expression within WAT in obese mice 
through RAR and PGC1 α (92), associated with increased mi-
tochondrial oxidative capacity. Furthermore, MEF (mouse em-
bryonic fi broblast)-derived adipocytes exhibited high mRNA 
expression of PRDM16 (93), which is known as one of the main 
transcriptional co-regulators controlling the development of 
brown adipocytes (4). 
 Th e fi nding that retinoids regulate a thermogenic program 
in WAT may have implications for future research on adipocyte 
diff erentiation and UCP1 gene expression in human adipose 
cells. Furthermore, these results may help elucidating the signal-
ing pathways of the UCP1 gene in an attempt to fi nd ways for 
stimulation of adaptive thermogenesis, with potential therapeutic 
implications. 
 Vascular endothelial growth factor (VEGF) 
 Recent insights have suggested a role for vascular endothelial 
growth (VEGF) in BAT functioning. VEGF is a family of signal 
proteins that stimulate vasculogenesis and angiogenesis. Th e VEGF 
family includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, 
and placental growth factor (PIGF) (94). Normally these factors 
are released in response to hypoxia, but recent studies indicate 
that VEGF is released from adipose tissue in response to cold, in a 
process to facilitate oxygen delivery and to promote heat exchange. 
Th e VEGF-A member is known to be associated with embryonic 
development. Furthermore, this subtype is highly expressed in 
adipose tissue and seems to be related to obesity (95). Th e B-type 
VEGF is involved in energy metabolism regulation and has recently 
been found to regulate fatty acid transport proteins through VEGF 
receptor 1 and neuropilin. VEGF-B knock-out mice have been as-
sociated with decreased fat accumulation in BAT and increased 
deposition in WAT (96). In a recent study (97) a genetic mouse 
model of repressed VEGF-A was used to study VEGF-regulated 
energy metabolism in white adipose tissue. VEGF repression 
seemed to be associated with lower food effi  ciency, lower body 
weight, and resistance to high-fat-diet-induced obesity. Further-
more, development of brown-like adipocytes within WAT took 
place in VEGF-repressed mice, with up-regulation of BAT-specifi c 
genes like PRDM16, BMP7, and UCP1 and down-regulation of 
WAT-specifi c genes like, leptin suggesting a role for VEGF in the 
diff erentiation of WAT into BAT. Another recent study showed 
that VEGF expression increases concomitantly with brown 
adipocyte diff erentiation (98). In cultured brown adipocytes VEGF 
promoted cell survival and proliferation. VEGF-A repression was 
accompanied by up-regulation of VEGF-B. 
 VEGF-A overexpression in mouse adipose tissue promotes a 
 ‘ BAT-like ’ phenotype in WAT depots, accompanied by increased 
BAT PGC1 α and UCP1 expression, potentiating increased 
thermogenesis and energy expenditure. Human evidence is lack-
ing and human studies on VEGF eff ects on BAT functioning 
are needed. VEGF-A and VEGF-B seem to be counteractively 
working against each other in energy balance metabolism, and 
this topic should receive more scientifi c attention in the future in 
order to elucidate the mechanisms by which VEGFs are involved 
in adipose tissue metabolism. 
 Perspective and therapeutic/clinical impact 
 Currently, brown adipose tissue is recognized as a potential 
weight loss inducer. Especially ways to activate BAT from inside 
the body, via endogenous substances and hormones, have re-
cently attracted the attention of research groups throughout the 
world. Involvement of the sympathetic nervous system, thyroid 
acid synthesis, by acting through the FGFR4/Klotho- β receptor 
complexes in the liver to inhibit CYP7A1 (cytochrome P450 7A1) 
(81). FGF19 also has metabolic eff ects, aff ecting glucose me-
tabolism when used in experimental mouse models (82). Th ese 
fi ndings show that the FXR receptor might be involved in the 
pathogenesis of metabolic syndrome. 
 BAs may also exert their function in peripheral tissues through 
another pathway involving TGR5 (transmembrane G protein-
coupled receptor 5). A recent study demonstrated increased EE in 
mice by oral ingestion of cholic acid, through BA binding to and 
activation of TGR5, a G-protein-coupled receptor (73). In BAT of 
mice and in human skeletal myocyte cultures, TGR5 activation 
stimulated intracellular cAMP formation and activated D2. D2 in 
turn converts the inactive thyroid hormone T4 (thyroxine) into 
the active T3 (3,5 ’,5-triiodo-I-thyronine) and stimulates energy 
expenditure in BAT (in rodents) and in skeletal muscle (in hu-
mans) (described above in section 3.2) (73). Human evidence for 
this suggestion is still limited and only a few studies have investi-
gated the relationship between BA and EE in humans. One study 
(83) found positive relations between circulating BAs and EE in 
a small group of healthy volunteers ( n    10). Another study (84) 
found no signifi cant eff ect of the BA sequestrant colesevelam for 
8 weeks on resting EE. 
 In summary, the interplay between BAs and the thyroid axis 
might be of importance for BAT activity. However, no prospec-
tive studies have confi rmed the strong relation between circulat-
ing BAs and BAT activity, as was observed in rodents, in humans 
yet. In order to develop new ways to target the obesity pandemic, 
future studies should address the interplay between bile acids and 
the thyroid axis and the possible benefi cial eff ects of activating 
this pathway on EE and BAT activities in humans. 
 Bone morphogenetic proteins (BMPs) 
 Bone morphogenetic factors (BMPs) are another group of novel 
promising targets for BAT-targeted anti-obesity therapy. BMPs 
belong to the transforming growth factor  β (TGF- β ) superfamily 
(85), and diff erent BMPs are known to act on specifi c cell types 
(86). In mice, BMP2 and BMP4 are known to stimulate white 
adipogenesis, by stimulating the commitment of mesenchymal 
cells to the adipocyte lineage and by driving preadipocyte diff er-
entiation into mature white adipocytes (87). BMP7 and BMP8b 
are involved in BAT functioning. BMP7 promotes brown-fat dif-
ferentiation in multipotent mesenchymal cells (88), and BMP8b is 
described to play a role in the direct regulation of thermogenesis 
(89). Mature brown adipocytes produce BMP8b in an attempt 
to amplify BAT thermogenic action in response to peripheral 
adrenergic activation. Strikingly, BMP8b is also expressed by the 
hypothalamus and acts centrally, increasing sympathetic output 
to BAT (89). Human evidence for a role of BMPs in BAT func-
tioning and diff erentiation is currently still lacking. 
 More research on pathways and mechanisms in which BMP8b 
can specifi cally increase energy dissipation by BAT is needed. 
 Retinoic acid 
 Recently the potential for adipocyte plasticity in terms of char-
acteristics specifi c to white or brown adipocytes remains under 
investigation. One of the factors of interest is retinoids. Retinoids 
are vitamin A (retinol) and  β -carotene metabolites, with diverse 
biological functions, like development, immune function, and 
vision (90). Th ey have recently been linked to energy homeostasis 
and adipogenesis control. Retinoic acid, which is formed from 
the vitamin A derivative retinaldehyde (Rald), activates the 
retinoic acid receptor (RAR) and retinoid X receptor (RXR), 
regulating gene expression in mice (91), adipocyte diff erentiation, 
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regulation of the BAT thermogenic program in WAT by these fac-
tors is needed. Even though the evidence in rodents points toward 
involvement of these factors in BAT functioning, human data are 
still lacking. Human studies are needed to assess the mechanisms 
by which these novel endogenous factors have implications for 
BAT-targeted anti-obesity treatment. 
 Th e interplay between the diff erent pathways described in this 
review points towards the need to target not only specifi c factors 
but to take into account these interactions. In rodents, activation 
of BAT through stimulation of some of these pathways has already 
been found to be eff ective. However, human evidence for eff ective 
methods of BAT activation is still lacking. Novel approaches for 
BAT activation as possible treatment options for obesity should 
be investigated in large human clinical trials. 
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hormones, FNDC5/irisin, cardiac natriuretic peptides, insu-
lin, FGF21, bile acids, BMPs, retinoic acid, and VEGFs in BAT 
activity and  ‘ browning ’ of WAT in humans has been discussed. 
Besides the direct eff ects these factors seem to have on BAT activ-
ity and  ‘ browning ’ of WAT in humans, some of them appear to be 
interconnected. 
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markedly increasing sympathetic activation of BAT (20). BAT 
activation through thyroid hormone is also under infl uence of 
the SNS system. Th e presence of D2 in BAT, which potentiates 
conversion of T4 into the metabolically active T3, is under direct 
control of norepinephrine. Furthermore, thyroid hormone seems 
to be a direct inducer of hypothalamic AMPK, which leads to 
enhanced SNS activation and  de novo lipogenesis, resulting in 
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human stem cells with T3 stimulated the development of UCP1-
positive cells within WAT, suggesting a role for thyroid hormone 
in  ‘ browning ’ of white adipose tissue. 
 Besides this SNS – thyroid hormone synergism, SNS activation 
also seems to be related to exercise, and associated irisin release, 
since exercise leads to massive SNS activation (99). However, 
most studies did not fi nd accompanying increase in BAT activity, 
and a recently published study seems to provide evidence against 
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BAT functioning. BNP infusion in mice was associated with 
increased energy expenditure and  ‘ browning ’ of WAT (39). In 
humans, circulating levels of NPs are negatively related to type 
2 diabetes incidence (100) and BMI (101), suggesting a protec-
tive role in the development of obesity and associated metabolic 
diseases. 
 In many animal models of obesity insulin resistance and 
defective BAT thermogenesis are clearly associated (56), but a 
direct causation between reduced NST and insulin resistance has 
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subjects found a negative association between BAT activity and 
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tion of WAT into BAT. More attention on the development and 
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